Advertisement


Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

2014 San Antonio Breast Cancer Symposium

Advertisement

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:

  • The TNT trial comparing docetaxel to carboplatin
  • The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
  • Pembrolizumab in a phase Ib study



Related Videos

Breast Cancer

Jack Cuzick, PhD, on the IBIS-I Trial

Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."

Breast Cancer

Lisa A. Carey, MD, on the TNT Trial

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01, “The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer."

Breast Cancer

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, Discuss the SOFT Trial

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.

Breast Cancer

Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “Stage 1 results from MDV3100-11: A two-stage study of enzalutamide, an androgen receptor inhibitor, in advanced androgen receptor–positive triple-negative breast cancer,” presented by Tiffany A. Traina, MD.

Breast Cancer

Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, on abstract S3-09, “Patient-reported endocrine symptoms, sexual functioning and quality of life in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen alone vs tamoxifen plus ovarian function suppression in premenopausal women with hormone receptor–positive early breast cancer.”

Advertisement

Advertisement




Advertisement